Regulus Therapeutics Inc.
RGLS
$2.06
$0.126.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -58.68% | -79.73% | -57.36% | -18.63% | -18.63% |
| Total Depreciation and Amortization | 14.47% | 60.71% | 89.36% | 68.75% | 130.30% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 104.93% | 91.72% | 169.91% | 197.92% | 242.57% |
| Change in Net Operating Assets | -244.09% | 401.68% | -758.16% | -6.61% | 297.18% |
| Cash from Operations | -93.39% | -50.53% | -86.13% | -7.74% | 2.05% |
| Capital Expenditure | 100.00% | 94.82% | -- | -22,800.00% | -12.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 380.00% | 481.14% | -- | -622.10% | -52.52% |
| Cash from Investing | 386.62% | 442.72% | -- | -623.66% | -52.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 33.29% | 0.00% | -- |
| Issuance of Common Stock | -- | -99.46% | -- | 447,190.48% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00% | -80.49% | -105.63% | 11,665.84% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 688.33% | 180.94% | -279.21% | -4.29% | -149.03% |